Bicycle Therapeutics BCYC
NASDAQ BCYC
$3.59 -0.10 (-2.70%)
As of: Nov 12, 2026 · 9:43 AM EST

Bicycle Therapeutics (BCYC) Return on Sales [ROS] (2018 - 2026)

Updated

Bicycle Therapeutics (BCYC) posted Return on Sales [ROS] of -8673.93% for Q2 2026, down 5708.10 percentage points from -2965.82% a year earlier and down 1291.51 percentage points from the prior quarter.

Analysis

Bicycle Therapeutics (BCYC) Return on Sales [ROS] (2018 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Return on Sales [ROS] at Bicycle Therapeutics was -343.60%, up 1151.73 percentage points year-over-year; for FY2025, it came in at -340.38%, up 254.58 percentage points from FY2024.

  • Annual Return on Sales [ROS] has increased for three consecutive years, with a five-year change of +159.72 percentage points (FY2020 to FY2025).
  • In prior years, Bicycle Therapeutics' Return on Sales [ROS] was -594.96% in FY2024 (+109.17 pp), -704.13% in FY2023 (+102.43 pp), -806.56% in FY2022 (-245.58 pp) and -560.98% in FY2021 (-60.89 pp).
  • The Q2 2026 figure stands as the lowest quarterly Return on Sales [ROS] in data going back to Q1 2018.
  • On a year-over-year basis, Return on Sales [ROS] increased in two of the last eight quarters, with an average year-over-year change of -1754.92 percentage points.
  • The strongest year-over-year quarter for Return on Sales [ROS] in the past five years was Q3 2025, with a gain of 1827.23 percentage points; the weakest was Q1 2026, with a drop of 6678.75 percentage points.
  • According to Business Quant data, Return on Sales [ROS] for the three prior quarters was -7382.41% (Q1 2026), -51.52% (Q4 2025) and -558.64% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 34.46%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 24.35%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 36.01%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 30.74%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 29.12%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 35.79%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 41.71%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 32.98%
10 Bicycle Therapeutics 258.27 Mn -1.91 Bn - -39.57%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -39.57%
Jun 30, 2026 -8,673.93%
Mar 31, 2026 -7,382.41%
Dec 31, 2025 -51.52%
Sep 30, 2025 -558.64%
Jun 30, 2025 -2,965.82%
Mar 31, 2025 -703.66%
Dec 31, 2024 -1,824.78%
Sep 30, 2024 -2,385.87%
Jun 30, 2024 -498.31%
Mar 31, 2024 -162.40%
Dec 31, 2023 -1,017.35%
Sep 30, 2023 -949.12%
Jun 30, 2023 -378.27%
Mar 31, 2023 -853.82%
Dec 31, 2022 -1,011.33%
Sep 30, 2022 -978.91%
Jun 30, 2022 -623.57%
Mar 31, 2022 -709.40%
Dec 31, 2021 -477.96%
API Access

Bicycle Therapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=BCYC&period=max&api_key=YOUR_API_KEY